Article thumbnail

Hormonal content and potency of oral contraceptives and breast cancer risk among young women

By M D Althuis, D R Brogan, R J Coates, J R Daling, M D Gammon, K E Malone, J B Schoenberg and L A Brinton
Topics: Epidemiology
Publisher: Nature Publishing Group
OAI identifier: oai:pubmedcentral.nih.gov:2376784
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1991). Breast cancer risk and oral contraceptive use: results from a large case–control study. Epidemiology 2: 353–358 White E,
  2. (2003). Cancer Research UKacting directly, alone or synergistically, on breast cells in vivo (Jeng
  3. (2003). Cancer Research UKHowever, progestin doses selected for use in current oral contraceptives are essentially equipotent (Collins,
  4. (1986). Oral contraceptive use and breast cancer in young women. A joint national case–control study in Sweden and Norway. Lancet 2: 650–654 Mishell Jr DR
  5. (1989). Oral contraceptives and breast cancer.
  6. Table 4 Breast cancer risk associated with hormonal potency and content of combination oral contraceptives used for the longest duration within 5 years of interview
  7. (2003). The ‘boom and bust phenomenon’: the hopes, dreams, and broken promises of the contraceptive revolution. Contraception 61: 9–25 Breslow NE, Day NE